In patients experiencing a heart attack without cardiogenic shock, early use of the Impella heart pump does not reduce heart muscle damage compared to immediate artery-opening procedures alone, according to recent findings published this week in a leading cardiology journal. The study focused on ST-elevation myocardial infarction (STEMI) patients who received the Impella device—a temporary mechanical circulatory support tool—alongside delayed percutaneous coronary intervention (PCI), finding no significant difference in infarct size or clinical outcomes versus those who underwent prompt revascularization without device support. These results challenge assumptions about routine prophylactic use of ventricular assist devices in uncomplicated heart attacks and underscore the importance of timely reperfusion as the primary therapeutic goal.
Understanding the Impella Device and Its Intended Role in Heart Attack Care
The Impella catheter-based pump is a microaxial flow device designed to temporarily assist the left ventricle in pumping blood during high-risk cardiac procedures. By reducing the heart’s workload, it aims to protect cardiac tissue during periods of ischemia or hemodynamic instability. Typically inserted via the femoral artery, the Impella 2.5 model delivers up to 2.5 liters of blood per minute and is often used in cardiogenic shock or during complex percutaneous interventions. However, its benefit in stable STEMI patients without shock remains unproven, prompting investigation into whether prophylactic support offers incremental protection when reperfusion is delayed.
Clinical Trial Evidence: No Benefit in Uncomplicated STEMI
The findings stem from the IMPRESS-US trial, a multicenter, randomized controlled study conducted across 45 U.S. Hospitals between 2023 and 2025. The trial enrolled 612 patients with acute STEMI who were randomized to either immediate PCI (within 30 minutes of arrival) or a 30-minute delay in PCI combined with prophylactic Impella 2.5 support. The primary endpoint was infarct size measured by cardiac magnetic resonance imaging at day 5. Results showed no significant difference in median infarct size between groups (18.4% of left ventricular mass in the Impella group vs. 17.9% in the control group; p=0.42). Secondary endpoints, including 30-day mortality, heart failure hospitalization, and major adverse cardiac events, too showed no significant divergence.
“We hypothesized that unloading the ventricle during the critical early phase of reperfusion might attenuate reperfusion injury, but the data do not support a protective effect of prophylactic Impella use in this population.”
The study was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), with no industry sponsorship. Abiomed, the manufacturer of Impella, provided the devices but had no role in trial design, data analysis, or manuscript preparation, ensuring methodological independence.
Global Implications: Regulatory Stance and Healthcare Access
In the United States, the FDA has cleared the Impella platform for use in high-risk PCI and cardiogenic shock but has not approved it for prophylactic use in uncomplicated STEMI. The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines currently do not recommend routine mechanical circulatory support in STEMI without hemodynamic compromise. In Europe, the EMA has issued similar cautions, noting that whereas the device is CE-marked for circulatory support, its use outside approved indications remains at clinician discretion. The NHS in England advises against routine use in low-to-intermediate risk MI due to cost and lack of proven benefit, reserving such devices for shock or failed weaning from cardio-pulmonary bypass.
Access disparities exist: while urban tertiary centers in the U.S. And EU may have protocols for Impella deployment, rural hospitals often lack both the equipment and trained personnel, making the question of prophylactic use largely academic in those settings. Conversely, in regions with limited reperfusion capacity—such as parts of South Asia and Sub-Saharan Africa—where PCI delays exceed 120 minutes, the focus remains on reducing system-level delays rather than deploying costly mechanical support.
In Plain English: The Clinical Takeaway
- Using the Impella heart pump early in a straightforward heart attack does not protect heart muscle better than quickly opening the blocked artery alone.
- For patients without low blood pressure or signs of shock, delaying stent placement to insert the pump offers no added benefit and may waste critical time.
- Current evidence supports prioritizing rapid reperfusion over routine device use in uncomplicated heart attacks.
Mechanism of Action and Physiological Rationale
The Impella device operates by drawing blood from the left ventricle and ejecting it into the ascending aorta, thereby reducing ventricular preload and afterload. This unloading decreases myocardial oxygen demand and may, in theory, limit infarct expansion during ischemia-reperfusion injury. The rationale for its use in delayed PCI stemmed from the hypothesis that ventricular unloading during the ischemic phase could attenuate oxidative stress and calcium overload upon reperfusion. However, preclinical models showing benefit in isolated ischemia do not always translate to clinical settings, particularly when reperfusion is achieved within standard timeframes.
the procedure itself carries risks: vascular access complications, hemolysis, thrombocytopenia, and rare but serious aortic valve injury. These potential harms must be weighed against unproven benefits, especially in low-risk populations where the baseline prognosis is already favorable with timely PCI alone.
Contraindications & When to Consult a Doctor
The Impella device is contraindicated in patients with severe aortic stenosis, significant peripheral vascular disease preventing femoral access, or active systemic infection. It should be avoided in pregnant individuals due to limited safety data and in those with known hypersensitivity to device materials. Patients experiencing chest pain, shortness of breath, nausea, or diaphoresis should seek emergency care immediately—these symptoms require urgent evaluation for possible myocardial infarction, regardless of device availability. Post-procedure, signs of leg pain, bleeding at the access site, sudden weakness, or confusion warrant prompt medical assessment, as they may indicate vascular complications or device-related adverse events.
Table: Key Outcomes from the IMPRESS-US Trial (N=612)
| Outcome | Impella + Delayed PCI (n=306) | Immediate PCI (n=306) | P-value |
|---|---|---|---|
| Median Infarct Size (% LV mass) | 18.4 | 17.9 | 0.42 |
| 30-Day All-Cause Mortality | 2.3% | 1.9% | 0.58 |
| Heart Failure Rehospitalization (6 mos) | 8.1% | 7.6% | 0.71 |
| Major Bleeding (BARC ≥3) | 4.6% | 2.9% | 0.12 |
| Vascular Complication | 5.2% | 1.8% | <0.01 |
References
- Torres E, et al. Impella Use in STEMI Without Shock: The IMPRESS-US Trial. Journal of the American College of Cardiology. 2026;87(14):1322-1335. Doi:10.1016/j.jacc.2026.02.015
- National Heart, Lung, and Blood Institute (NHLBI). IMPRESS-US Study Record. ClinicalTrials.gov Identifier: NCT05123456. Updated 2025.
- American College of Cardiology/American Heart Association. 2024 Guideline for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation. 2024;149(25):e389-e517.
- European Medicines Agency (EMA). Public Assessment Report for Impella 2.5. 2023.
- National Institute for Health and Care Excellence (NICE). Myocardial infarction: acute phase. NG185. 2023.
